Methane-Oxidizing Activity Enhances Sulfamethoxazole Biotransformation in a Benthic Constructed Wetland Biomat.

Ammonia monooxygenase and analogous oxygenase enzymes contribute to pharmaceutical biotransformation in activated sludge. In this study, we hypothesized that methane monooxygenase can enhance pharmaceutical biotransformation within the benthic, diffuse periphytic sediments (i.e., "biomat") of a shallow, open-water constructed wetland. To test this hypothesis, we combined field-scale metatranscriptomics, porewater geochemistry, and methane gas fluxes to inform microcosms targeting methane monooxygenase activity and its potential role in pharmaceutical biotransformation. In the field, sulfamethoxazole concentrations decreased within surficial biomat layers where genes encoding for the particulate methane monooxygenase (pMMO) were transcribed by a novel methanotroph classified as Methylotetracoccus. Inhibition microcosms provided independent confirmation that methane oxidation was mediated by the pMMO. In these same incubations, sulfamethoxazole biotransformation was stimulated proportional to aerobic methane-oxidizing activity and exhibited negligible removal in the absence of methane, in the presence of methane and pMMO inhibitors, and under anoxia. Nitrate reduction was similarly enhanced under aerobic methane-oxidizing conditions with rates several times faster than for canonical denitrification. Collectively, our results provide convergent in situ and laboratory evidence that methane-oxidizing activity can enhance sulfamethoxazole biotransformation, with possible implications for the combined removal of nitrogen and trace organic contaminants in wetland sediments.

Scalable and customizable parallel flow-through reactors to quantify biological processes related to contaminant attenuation by photosynthetic wetland microbial mats.

Shallow, unit process open water wetlands harbor a benthic microbial mat capable of removing nutrients, pathogens, and pharmaceuticals at rates that rival or exceed those of more traditional systems. A deeper understanding of the treatment capabilities of this non-vegetated, nature-based system is currently hampered by experimentation limited to demonstration-scale field systems and static lab-based microcosms that integrate field-derived materials. This limits fundamental mechanistic knowledge, extrapolation to contaminants and concentrations not present at current field sites, operational optimization, and integration into holistic water treatment trains. Hence, we have developed stable, scalable, and tunable laboratory reactor analogs that offer the capability to manipulate variables such as influent rates, aqueous geochemistry, light duration, and light intensity gradations within a controlled laboratory environment. The design is composed of an experimentally adaptable set of parallel flow-through reactors and controls that can contain field-harvested photosynthetic microbial mats ("biomat") and could be adapted for analogous photosynthetically active sediments or microbial mats. The reactor system is contained within a framed laboratory cart that integrates programable LED photosynthetic spectrum lights. Peristaltic pumps are used to introduce specified growth media, environmentally derived, or synthetic waters at a constant rate, while a gravity-fed drain on the opposite end allows steady-state or temporally variable effluent to be monitored, collected, and analyzed. The design allows for dynamic customization based on experimental needs without confounding environmental pressures and can be easily adapted to study analogous aquatic, photosynthetically driven systems, particularly where biological processes are contained within benthos. The diel cycles of pH and dissolved oxygen (DO) are used as geochemical benchmarks for the interplay of photosynthetic and heterotrophic respiration and likeness to field systems. Unlike static microcosms, this flow-through system remains viable (based on pH and DO fluctuations) and has at present been maintained for more than a year with original field-based materials.•Lab-scale flow-through reactors enable controlled and accessible exploration of shallow, open water constructed wetland function and applications.•The footprint and operating parameters minimize resources and hazardous waste while allowing for hypothesis-driven experiments.•A parallel negative control reactor quantifies and minimizes experimental artifacts.

Pharmaceutical Biotransformation is Influenced by Photosynthesis and Microbial Nitrogen Cycling in a Benthic Wetland Biomat.

In shallow, open-water engineered wetlands, design parameters select for a photosynthetic microbial biomat capable of robust pharmaceutical biotransformation, yet the contributions of specific microbial processes remain unclear. Here, we combined genome-resolved metatranscriptomics and oxygen profiling of a field-scale biomat to inform laboratory inhibition microcosms amended with a suite of pharmaceuticals. Our analyses revealed a dynamic surficial layer harboring oxic-anoxic cycling and simultaneous photosynthetic, nitrifying, and denitrifying microbial transcription spanning nine bacterial phyla, with unbinned eukaryotic scaffolds suggesting a dominance of diatoms. In the laboratory, photosynthesis, nitrification, and denitrification were broadly decoupled by incubating oxic and anoxic microcosms in the presence and absence of light and nitrogen cycling enzyme inhibitors. Through combining microcosm inhibition data with field-scale metagenomics, we inferred microbial clades responsible for biotransformation associated with membrane-bound nitrate reductase activity (emtricitabine, trimethoprim, and atenolol), nitrous oxide reduction (trimethoprim), ammonium oxidation (trimethoprim and emtricitabine), and photosynthesis (metoprolol). Monitoring of transformation products of atenolol and emtricitabine confirmed that inhibition was specific to biotransformation and highlighted the value of oscillating redox environments for the further transformation of atenolol acid. Our findings shed light on microbial processes contributing to pharmaceutical biotransformation in open-water wetlands with implications for similar nature-based treatment systems.